Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AstraZeneca PLC (NYSE:AZN)

31.13
Delayed Data
As of Jul 22
 +0.60 / +1.97%
Today’s Change
26.97
Today|||52-Week Range
34.88
-8.31%
Year-to-Date
European Stock Markets Mixed After Signs of Brexit Damage
Jul 22 / TheStreet.com - Paid Partner Content
AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint
Jul 19 / Zacks.com - Paid Partner Content
Sorry, You Can't Buy This Hot Biotech -- At Least Not Directly
Jul 21 / MotleyFool.com - Paid Partner Content
Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
Jul 18 / Zacks.com - Paid Partner Content
Why Shares of Relypsa Are Soaring Today
Jul 21 / MotleyFool.com - Paid Partner Content
Is This Gilead Sciences' Most Underappreciated Drug Candidate?
Jul 18 / MotleyFool.com - Paid Partner Content
Relypsa Finally Finds Buyer, But Potential Seen For Rival Bid
Jul 21 / TheStreet.com - Paid Partner Content
Is Advaxis' Stock Now a Bargain?
Jul 15 / MotleyFool.com - Paid Partner Content
Heavy Volume And Pre-Market Movement For AstraZeneca (AZN)
Jul 21 / TheStreet.com - Paid Partner Content
3 Dividend Aristocrats to Avoid
Jul 14 / MotleyFool.com - Paid Partner Content
AstraZeneca (AZN) Is Today's Storm The Castle Stock
Jul 20 / TheStreet.com - Paid Partner Content
Why Inovio Pharmaceuticals' Stock Plunged in June
Jul 14 / MotleyFool.com - Paid Partner Content
Valeant/Progenics Relistor Ok'd; FDA Panel Backs Brodalumab
Jul 20 / Zacks.com - Paid Partner Content